Single dose of ayahuasca or esketamine could ease PTSD symptoms

NCT ID NCT07317206

Recruiting now Symptom relief Sponsor: University of Sao Paulo Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single dose of ayahuasca or esketamine can reduce symptoms of posttraumatic stress disorder (PTSD). Ten adults with PTSD will receive one of the two drugs in a double-blind design. The goal is to see if either substance can provide rapid relief from PTSD symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ayahuasca or esketamine
What this could lead to: If it works, this could point toward a new, fast-acting treatment option for PTSD that uses a single dose.
What could go wrong: This is a very small early-phase trial with only 10 participants, so results may not apply widely. Both substances can cause intense psychological effects and are not proven safe or effective for PTSD yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTTRAUMATIC STRESS DISORDER (PTSD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTTRAUMATIC STRESS DISORDER (PTSD)

Contacts and locations

Locations

Hospital das Clínicas da FMRP-USP
RECRUITING

Ribeirão Preto, São Paulo, 14049900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.